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ABSTRACT
This article provides an overview of radiofrequency abla-
tion (RFA) and microwave ablation (MWA) for treatment of
primary liver tumors and hepatic metastasis. Only studies
reporting RFA and MWA safety and efficacy on liver were
retained. We found 40 clinical studies that satisfied the
inclusion criteria. RFA has become an established treat-
ment modality because of its efficacy, reproducibility, low
complication rates, and availability. MWA has several
advantages over RFA, which may make it more attractive
to treat hepatic tumors. According to the literature, the
overall survival, local recurrence, complication rates,
disease-free survival, and mortality in patients with hepato-
cellular carcinoma (HCC) treated with RFA vary between
53.2  3.0 months and 66 months, between 59.8% and
63.1%, between 2% and 10.5%, between 22.0  2.6 months
and 39 months, and between 0% and 1.2%, respectively.
According to the literature, overall survival, local recurrence,
complication rates, disease-free survival, and mortality in
patients with HCC treated with MWA (compared with RFA) vary
between 22 months for focal lesion >3 cm (vs. 21 months)
and 50 months for focal lesion ≤3 cm (vs. 27 months),
between 5% (vs. 46.6%) and 17.8% (vs. 18.2%), between
2.2% (vs. 0%) and 61.5% (vs. 45.4%), between 14 months
(vs. 10.5 months) and 22 months (vs. no data reported),
and between 0% (vs. 0%) and 15% (vs. 36%), respectively.
According to the literature, the overall survival, local recur-
rence, complication rates, and mortality in liver metastases
patients treated with RFA (vs. MWA) are not statistically
different for both the survival times from primary tumor
diagnosis and survival times from ablation, between 10%
(vs. 6%) and 35.7% (vs. 39.6), between 1.1% (vs. 3.1%) and
24% (vs. 27%), and between 0% (vs. 0%) and 2% (vs. 0.3%).
MWA should be considered the technique of choice in
selected patients, when the tumor is ≥3 cm in diameter
or is close to large vessels, independent of its size. The
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Implications for Practice: Although technical features of the radiofrequency ablation (RFA) and microwave ablation (MWA)
are similar, the differences arise from the physical phenomenon used to generate heat. RFA has become an established
treatment modality because of its efficacy, reproducibility, low complication rates, and availability. MWA has several advan-
tages over RFA, which may make it more attractive than RFA to treat hepatic tumors. The benefits of MWA are an improved
convection profile, higher constant intratumoral temperatures, faster ablation times, and the ability to use multiple probes
to treat multiple lesions simultaneously. MWA should be considered the technique of choice when the tumor is ≥3 cm in
diameter or is close to large vessels, independent of its size.
INTRODUCTION
Tumor ablation is a minimally invasive approach that is
commonly employed in the treatment of hepatic tumors [1].
Ablation therapy is considered a potential first-line treatment in
many patients with small hepatocellular carcinomas [2] or an
alternative for people who are not fit for surgical resection or
have failed chemotherapy [3]. Moreover, tumor ablation can
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also be useful as an adjuvant therapy or may provide an alter-
native strategy to surgery or be used in association with re-
section in case of patients with poor functional liver reserve
(FLR) [3]. Most ablation systems comprise a generator and an
electrode (needle-like device) that delivers the energy directly
to the target area to cause tissue necrosis. Typically, treatments
can be performed percutaneously under image guidance by
inserting the electrode into the target area and applying energy
to induce coagulative necrosis. Ablation may also be performed
laparoscopically or via open surgery [4].
Radiofrequency ablation (RFA), microwave ablation
(MWA), high-intensity focused ultrasound, and laser ther-
apy are hyperthermic procedures that apply energy to heat
the tissue to at least 60C for maximum efficacy, whereas
the cryoablation systems is hypothermic, cooling the tissue
to less than −40C to cause necrosis [4, 5]. The most clini-
cally verified and used ablation modalities are RFA and
MWA. Each of these technologies has its own strengths and
weaknesses when applied to treatment of tumors in a vari-
ety of solid organs [4, 5].
The primary endpoint of ablation therapy is to obtain a
complete necrosis (similar to R0 resection) of liver tumors
that is linked to create a safety margin of at least 10 mm
round the external margin of the lesion. However, the effec-
tiveness of the treatment is linked to numerous features,
such as tumor size, location, blood flow, and equipment uti-
lized [5]. RFA is a widely employed procedure to treat both
primary and metastatic hepatic tumors [6, 7]. MWA is a
new procedure that has similar benefits of the RFA, with
several advantages, such as a greater volume of cellular
necrosis, procedure time reduction, and higher temperatures
delivered to the target lesion, and is less susceptible to varia-
tion in the morphology of the treatment zone because of heat-
sink effects from adjacent vasculature. However, with larger
zones of necrosis, it increases the risk of potential complication
owing to collateral injury to adjacent nontarget organs [8, 9].
So, with adequate physician experience and hospital financial
resources allowing the opportunity for acquisition of MWA
technology, more effective treatment of larger tumors in a
timely and efficient manner can be performed [5].
This overview is an independent study and did not
require institutional review board approval and registration
number.
SEARCH CRITERION
Numerous electronic datasets were examined: PubMed (U.S.
National Library of Medicine, http://www.ncbi.nlm.nih.gov/
pubmed), Scopus (Elsevier, http://www.scopus.com/), Web of
Science (Thomson Reuters, http://apps.webofknowledge.com/),
and Google Scholar (https://scholar.google.it/). The following
search criteria were used: “radiofrequency ablation” AND “Liver”
AND “HCC” AND “metastasis,” “microwave ablation,” AND
“Liver” AND “HCC” AND “metastasis,” “radiofrequency ablation”
AND “Liver” AND “complication,” “microwave ablation” AND
“Liver” AND “complication,” “radiofrequency ablation” AND
“Liver” AND “safety” AND “efficacy,” “microwave ablation”
AND “Liver” AND “safety” AND “efficacy”. The research cov-
ered the years from January 1990 to June 2017.
All titles and abstracts were analyzed, and only the stud-
ies reporting RFA and MWA safety and efficacy on liver
tumors were retained.
The inclusion criteria were clinical study evaluating RFA
safety and efficacy to treat liver metastases, clinical study
evaluating RFA safety and efficacy to treat hepatocellular
carcinoma (HCC), clinical study evaluating MWA safety and
efficacy to treat liver metastases, and clinical study evaluat-
ing MWA safety and efficacy to treat HCC. Articles pub-
lished in the English language from January 1990 to June
2017 were included. Exclusion criteria were unavailability of
full text, general overview articles, and congress abstracts.
We identified 4,320 potentially relevant references through
electronic searches. After removing 2,180 duplicates, we ob-
tained 2,140 references. We identified 15 references through
scanning reference lists of the identified randomized trials that
we added to the 2,140 references previously selected (total num-
ber of scrutinized articles was 2,155). We then excluded 2,040
clearly irrelevant articles through screening titles and reading
abstracts. We retrieved 100 references for further assessment.
We excluded 75 references for the reasons listed in the exclusion
criteria. A total of 40 clinical trials met the inclusion criteria. The
reference flow is summarized in the study flow diagram (Fig. 1).
BACKGROUND
Although the technical features of RFA andMWA are similar, the
differences arise from the physical phenomenon used to gener-
ate heat. RFA causes cellular death thanks to thermocoagulation
necrosis. MWA is based on dielectric heating. The major distinc-
tion between RFA and MWA heating is that during MWA treat-
ment heat is contained in a volume around the applicator
antenna, whereas during RFA, it is restricted to areas of high cur-
rent density [10]. Radiofrequency (RF) heating needs an electri-
cally conductive pathway, which is not necessary during MWA
because microwaves can propagate through tissues without
conductivity. This means that low-conductivity tissues inhibit or
reduce RF current flow, whereas they do not modify microwave
propagation [10]. Microwaves also offer upgraded techniques
for multiple-applicator ablation. Volume heating means that
multiple antennas can be activated uninterruptedly and all
together nearby, or in distinct sites. When electromagnetic
Figure 1. Study flow diagram showing the included and
excluded studies in the systematic review.
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fields are overlapped, heating rises by N2, where N is the num-
ber of fields applied [4, 10]. Presently, RFA needs switching
between electrodes when multiple antenna are applied [6–10].
An essential feature when comparing RF and MWA will be the
tumor’s host organ and site within the organ; in fact, the tissue
properties of ablated area and normal tissue are dissimilar and
should be evaluated for both RF andMWA [4–10].
PHYSICAL PRINCIPLES
Radiofrequency Ablation
RFA causes cellular death thanks to thermocoagulation necro-
sis. Heat is produced by ionic excitement and impact rela-
tional to strength of applied energy. At present, two types of
RFA devices are clinically used. Monopolar (MP) RFA employs
a unique antenna, whereas bipolar (BP) RFA uses dual anten-
nas, or two electrodes on the same antenna facing each
other. Monopolar RFA is generally used for liver cancer abla-
tion. Recently, BP-RFA findings have shown ablation of a
much larger tumor volume in comparison with MP in a single
ablation, and BP-RFA is less affected by heat-sink effect com-
pared with MP [10]. According to the size and the shape of
the needle’s tip, a spherical ablated area is generated in
about 10–30 minutes, generally from 2 to 5 cm in diameter
[11]. With RFA, the zone of active tissue heating is limited to
a few millimeters surrounding the active electrode, with the
remainder of the ablation zone being heated via thermal con-
duction [10, 11]. With an increase in the size of the target
area, the efficacy of the treatment is reduced, as the maxi-
mum result is obtained for volumes less than 3.5 cm [12, 13].
Moreover, some tissue properties, such as electrical conduc-
tivity, thermal conductivity, dielectric permittivity, heat capac-
ity, and blood perfusion rate, have substantial effect on the
growth of ablation zones. Additionally, as the ablation pro-
gresses, the tissue can become dehydrated and charred, which
can increase tissue impedance to electrical current flow [4, 5].
So, RFA is limited by increasing in impedance and an excessive
local temperature [12, 13]. Several technical devices exist to
avoid this effect, such as monitoring temperature or imped-
ance during procedure or simultaneously instilling saline solu-
tion into the tissue surrounding the RF needle [14].
Microwave Ablation
MWA is based on dielectric heating, which occurs when an
imperfect dielectric material is exposed to an alternating
electromagnetic (EM) field [4, 15]. A microwave (MW) field
oscillates rapidly (2,450 MHz = 2.45 billion times a second),
rotating polar molecules, primarily water, that oscillate out
of phase, so some EM energy is absorbed and changed to
heat. During treatment, MWA produces EM waves around
an insulated, electrically independent antenna. The majority
of the heat is due to the excitement of polar water particles,
whereas ionic polarization influences for a much smaller part
of the generated heat [16, 17]. The MWA’s devices use fre-
quencies ≥900 MHz. The two main frequency categories used
are 915 and 2,450 MHz. The category of 2,450 MHz is the
one most commonly employed, whereas 915 MHz can pro-
duce deeper penetration, thus potentially creating larger abla-
tion zones [18]. MW energy creates a larger zone of active
heating (up to 2 cm surrounding the antenna) permitting
more uniform necrosis in the target lesion. MWA has some
theoretical benefits compared with RFA: the target to be
treated can be larger because it produces a larger area of
necrosis; the time of treatment is shorter; and MWA is less
influenced by the defense of the neighboring tissues due to
vaporization and charring, so as the heat-sink effect influences
less the efficacy of treatment. Because of the EM nature of
microwaves, MWA is not limited by tissue conductance, as
the propagation of energy is not dependent on electrical tis-
sues properties, unlike RFA treatment [19].
Heat-Sink Effect
Thermally ablative devices coagulate and cause necrosis tis-
sue with two distinct heating zones: an active heating zone
and a passive heating zone. The active heating zone occurs
within the tissue nearest to the device where the intensity
of energy is high and its absorption by tissue is fast, whereas
the passive zone occurs outside the active zone, further from
the ablation device where the intensity of energy is lower.
Passive zone extension beyond the active zone is determined
by local physiology and its inherent ability to circumvent
thermally damaging temperatures [20, 21]. Ablating focal
lesions adjacent to large vasculature is a particularly difficult
task. To fully understand this phenomenon, the heat-sink
effect should be thought of from both thermal and electrical
perspectives [22]. The thermal effect impacts both current-
and field-based technologies. Consider flowing blood through
a volume of heated tissue will draw the heat away through
convection and temperature differences, countering the abla-
tive effect. Thermal sink is particularly problematic when the
passive zone is relied upon to ablate tissue around a vessel. In
these cases, the lower energy intensity within the passive
zone is not able to achieve thermally toxic temperatures in
proximity to the cooling vasculature [22]. With RFA current-
based technologies, ablation near large vessels is not rec-
ommended, as the combined effect of electrical and thermal
sink dramatically increases the risk of incomplete necrosis of
malignant cells and local recurrence [23].
MWA field-based technologies, in contrast, have found a
niche in achieving coagulation of tissue around large vascula-
ture, as this energy source is not challenged by the energy sink
effect [24, 25]. For both RFA and MWA, however, attempting
to ablate tissue around a vessel with a passive zone of ablation
will continue to be a losing battle in the face of thermal sink. If
the passive zone of ablation continues to be relied upon to
extend ablation volumes beyond active heating patterns, we
risk local recurrence rates remaining high [23–25]. Bhardwaj
et al. evaluated MW, RF, and cryoablation histologically and
found no perivascular hepatocyte survival with MW ablation
but did find perivascular hepatocyte survival within the ablated
volume for cryoablation and conspicuous perivascular hepato-
cyte survival within the RF ablation zones [26].
DISCUSSION
RFA causes cellular death thanks to thermocoagulation
necrosis; conversely, MWA is based on dielectric heating,
so that MW energy creates a larger zone of active heating
permitting more uniform necrosis in the target lesion
© AlphaMed Press 2019
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compared with RFA. MWA is not limited by tissue conduc-
tance, and is less influenced by the defense of the neighbor-
ing tissues so as the heat-sink effect influences less the
efficacy of treatment unlike RFA treatment.
Regarding patients with HCC, ablative treatment is ac-
cepted as the best therapeutic choice for nonsurgical patients
with early stage HCC. Patients are required to have either a
single tumor smaller than 5 cm or as many as three nodules
smaller than 3 cm each and no evidence of vascular invasion
or extrahepatic spread. In the scenario of metastatic disease,
percutaneous ablation is generally indicated for nonsurgical
patients with colorectal cancer metastases isolated to the
liver. The number of lesions should not be considered an abso-
lute contraindication to percutaneous ablation if successful
treatment of all metastatic deposits can be accomplished.
Tumor size is a prognostic feature to predict the outcome of
treatment. The target tumor should not exceed 3–4 cm in lon-
gest axis to ensure complete ablation with most of the cur-
rently available devices [13, 25]. Another important feature
that affects the success rate of ablative treatment is the ability
to ablate all viable tumor tissue and an adequate tumor-free
margin. To achieve rates of local tumor recurrence with these
treatment that are comparable to those obtained with hepatic
resection, physicians should produce a 360 degree, 1-cm-thick
tumor-free margin around each tumor. This cuff will assure
that all microscopic invasions around the periphery of a tumor
have been eradicated [13]. Thus, the target diameter of an
ablation must be ideally 2 cm larger than the diameter of the
tumor that undergoes treatment. Otherwise, multiple over-
lapping ablations can be performed [13, 26].
HCC and RFA
Among all the ablative procedures, RFA is a frontline tech-
nique for HCCs smaller than 20 mm (Table 1) [2]. Several
studies have evaluated the efficacy of RFA with respect to
resection and have established that RFA is a noninvasive
and effective ablative treatment [27–31]. Although these
studies focused on RFA as a stand-alone therapy contained
valuable information regarding treatment safety and
response, they lacked sufficient follow-up to define impor-
tant long-term outcomes such as survival. Only recently
have survival data become available on RFA-treated patients
with HCC. Large clinical series from Europe, the U.S., and Asia
have demonstrated 5-year post-RFA survival rates between
33% and 55%, comparable to those seen in series of hepatic
resection [27–31].
According to the literature, the overall survival, local recur-
rence, complication rates, disease-free survival, and mortality
in patients with HCC treated with RFA vary between
53.2 3.0 months and 66 months, between 59.8% and 63.1%,
between 2% and 10.5%, between 22.0  2.6 months and
39 months, and 0% and 1.2%, respectively.
Park et al. evaluated themorbidity, mortality, overall survival
(OS), and disease-free survival (DFS) rates in patients with HCC
patients who underwent RFA and hepatic resection (HR).
They found no significant difference between the two study
populations. The DFS rates of the HR group were significantly
higher than the RFA group. Multivariate analysis identified that
recurrence and portal hypertension were associated with OS
and that portal hypertension and increased serum α-fetoprotein
were factors significantly associated with DFS. They concluded
that the patients who underwent RFA had similar OS rates com-
pared with HR, confirming that RFA could be an alternative
treatment for patients with HCC smaller than 3.0 cm who are
not eligible for surgical resection [27]. Kim et al. evaluated
604 patients (273 underwent liver resection and 331 RFA). The
survival rates at 5 and 10 years for HR and RFA groups were
87.6% versus 82.1% and 59.0% versus 61.2%, respectively, with
a recurrence-free survival rates at 5 and 10 years of 60.6% versus
39.4% and 37.5% versus 25.1%, respectively. In the propensity
score-matched cohort (152 pairs), there were no differences in
HCC-specific survival, whereas recurrence-free survival again
differed between the treatment groups. This study demon-
strated that, although RFA carried a higher risk of treatment-site
recurrence than HR, it provided similar overall survival probabil-
ity in patients with a single small HCC without a raised bilirubin
level or portal hypertension [28].
Gavriilidis et al. compared the survival benefits and
treatment efficacy of repeat hepatic resection (RHR) and
RFA for recurrent HCC. They evaluated five retrospective
studies including 639 patients and demonstrated that there
were no differences in DFS and OS. Comparison between
the two groups demonstrated similar 5-year DFS and 5-year
OS. However, RFA had a lower morbidity rate (2%) com-
pared with RHR (17%) [32].
Several comparative trials also have been conducted
evaluating RFA against other conventional ablative modali-
ties. The majority of these studies originated in East Asia
and compare RFA with the standard chemical ablation tech-
niques. Dong et al. completed a meta-analysis comparing
clinical outcomes between HR and ablation therapies (AT) for
small HCC. They evaluated 12 studies that involved 1952
patients (HR vs. AT), five studies that involved 701 patients
Table 1. Overall survival, local recurrence, complication rates, disease-free survival, and mortality in patients with HCC
treated with RFA
Study OS; 1, 3, 5 yr OS rates, %
Local
recurrence, %
Complications
rates, %
DFS; 1, 3, 5 yr OS
rates, % Mortality, %
Park et al. [27] 53.2  3.0 mo 63.1 10.5 22.0  2.6 mo 0
Kim et al. [28] 66 mo 59.8 – 39 mo –
Liu et al. [29] 97, 83, 66 63 – – –
Wang et al. [30] 91.6, 73.5, 57.4 57 – 67.1, 46.4, 38.0 –
Gory et al. [31] –, 62, 37 (for ≤5 cm HCC);–,
66, 39 (for ≤3 cm HCC)
– 2 – –
Abbreviations: –, not applicable; DFS, disease-free survival; HCC, hepatocellular carcinoma; mo, months; OS, overall survival; yr, year.
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(RFA vs. percutaneous ethanol injection [PEI]), and five addi-
tional studies (RFA vs. RFA + transcatheter arterial chemo-
embolization [TACE]) that all addressed the treatment of
small HCC. In HR versus AT, the authors found no significant
difference in OS rate at 1-year; however, there was a signifi-
cant rise in the HR group in OS rate at 5 years. They found no
significant differences between the two groups in disease-
free survival rates at 1 year and 5 years, whereas the HR
group showed higher disease-free survival rate at 3 years. In
studies of RFA versus PEI, the results showed that RFA proce-
dure was connected with significantly higher 2-year OS rates;
however, there were no significant differences in the 1-year
OS rate or incidence of complications. In studies of RFA versus
RFA + TACE, they found no significant differences in the
1-year or 3-year OS rate; however, the 5-year OS rate was
higher in the RFA + TACE group than the RFA group. The
results also showed that the incidence of complications after
AT was lower than that in the HR population, which might be
due to specific features of these therapies. The local recur-
rence rate was higher after RFA than after HR, which highlights
the importance of patient selection, tumor size, vascular abut-
ment, and thorough treatment when using RFA. Dong et al.
concluded that RFA is the best single ablation technique. How-
ever, RFA plus TACE were better than RFA alone for the treat-
ment of small HCC [33].
Hung et al. evaluated the clinical outcomes of Hepatic
resection and ablative procedures in elderly patients with
HCC (defined as aged ≥70 years) [34]. They investigated
23 studies that included 12,482 patients. A total of 6,341
patients were subjected to HR, 3,138 to RFA, and 3,003 to
TACE. Among the HR group, the elderly had significantly
more respiratory comorbidities compared with that youn-
ger group, whereas there were no significant differences of
cardiovascular comorbidities and diabetes between the two
groups. At 1 year, the elderly patients had significantly
increased survival rates after HR than the younger patients.
However, Hung et al. showed that there were not significant
differences of the survival outcomes with HR between
elderly and nonelderly patients at 3 years and 5 years. When
they evaluated postoperative complications, they showed that
the rate were comparable between the elderly and younger
patients. Conversely, among the RFA group, the elderly and
nonelderly patients showed similar survival outcomes for the
first and third year, whereas elderly patients had significantly
worse survival rates than nonelderly patients for the fifth year.
Among the TACE group, the elderly showed significantly
increased survival compared with the nonelderly patients for
the first and third year, whereas the researchers showed that,
at the fifth year, there were no significant differences in overall
survival between all patients [34]. These studies demonstrated
that RFA-treated patients showed significantly better recur-
rence and survival rates than their chemically ablated counter-
parts. Furthermore, the number of treatment sessions required
to induce complete response was significantly less in the RFA
treatment group. Although RFA was superior to chemical abla-
tion in terms of inducing responses, limiting recurrence, and
prolonging survival, it was associated with a higher complica-
tion rate [31–34].
Salhab et al. suggested that RFA should be the first-line
treatment in patients with a single small HCC tumor ≤3 cm.
However, when the tumors is greater than 3 cm, RFA is
characterized by high incomplete ablation and local recur-
rence rates, [35]. A meta-analysis of 95 studies including
5,224 liver tumors treated by RFA reported a local recur-
rence rate of 12.4%. Local recurrence was substantially
higher following treatment of tumors >3–5 cm (24.1 %)
or >5 cm (58.1 %) in diameter [36].
HCC and MWA
With the microwave technology progress and a continu-
ously cooled electrode development, MWA has recently
been used more recurrently in treatment of HCC (Fig. 2,
Table 2) [4, 10, 19].
According to the literature, overall survival, local recur-
rence, complication rates, disease-free survival, and mortality in
patients with HCC treated with MWA (compared with RFA)
vary between 22 months for focal lesion >3 cm (vs. 21 months)
and 50 months for focal lesion ≤3 cm (vs. 27 months), between
5% (vs. 46.6%) and 17.8% (vs. 18.2%), between 2.2 % (vs. 0%)
and 61.5% (vs. 45.4%), between 14 months (vs. 10.5 months)
and 22 months (vs. no data reported), and between 0%
(vs. 0%) and 15% (vs. 36%), respectively.
Baker et al. assessed safety and efficacy of MWA in 340
patients with HCC. Median value of lesion size was 3.2 cm
(range, 1–6). A total of 89.5% of patients had cirrhosis, 60.7%
related to hepatitis C, and 8.2% related to hepatitis B. Slightly
over one third (35.9%) were Child-Pugh class B/C cirrhotic. Lap-
aroscopic MWA procedures were performed in 96.8% of the
patients. Four patients died within 30 days (1.8%). Clavien-
Dindo grade III complications happened in 3.2% of patients.
Complete necrosis was recognized in 97.1% of tumors, whereas
local recurrence was 8.5% at 10.9 months median follow-up
(0–80 months). Local recurrence happened in 34.8% of patients
at 10.9 months median follow-up, and metastatic recurrence
rate was appreciated in 8.1% of patients. At 1 year, OS was
80.0%, whereas at 2 years OS was 61.5%. The researchers
established that MWA could be performed safely, even in
patients with advanced disease. The minimally invasive proce-
dure determines low morbidity and mortality with acceptable
incomplete necrosis rates and regional recurrence [37].
Swan et al. assessed MWA in the treatment of 54 patients
with HCC (73 tumors) with advanced disease. Median value
of tumor size was 2.6 cm (range, 0.5–8.5). A total of 92.6%
of patients had cirrhosis; among these, 27.8% had a Child-
Pugh score of B/C and 59.3% had chronic hepatitis C. A mini-
mally invasive procedure was performed in 94.5%. The authors
showed that there were no deaths within 30 days. The 30 days
morbidity frequency was 28.9%, with grade III complications in
11.5% of cases. A total of 7.8% of patients reported delayed
complications, with a mortality percentage of 5.6% at 90 days.
Incomplete necrosis was found in 5.9% of lesions, with a local
recurrence percentage of 2.9% at 9 month median follow-up.
Local and metastatic recurrence was detected in 27.5% and
11.8% at 9-month median follow-up. Median OS was not
reached at 11-month median follow-up. One- and 2-year OS
frequencies were 72.3% and 58.8%, respectively. The re-
searchers showed that MWA could be performed safety in
HCC lesions [38].
According to Swan et al. [38], previous studies proved
that MWA is safe in both percutaneous and open settings
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[39–41]. Liang et al. testified a mortality frequency of 0.2%
and a major complication percentage of 2.6% following per-
cutaneous ultrasound-guided MWA in 1,136 patients with
1,928 primary and secondary liver tumors over 13 years
[39]. Regional recurrence following MWA may be equivalent
or lower than RFA [42–44]. Simo et al. compared safety and
efficacy of laparoscopic-assisted (Lap) MWA with Lap-RF.
They evaluated 35 patients with HCC. Twenty-seven tumors
in 22 patients were subjected to Lap-RFA, whereas 13
patients (15 tumors) received Lap-MWA. Average ablation
Figure 2. A 53-year-old man with hepatocellular carcinoma on IV hepatic segment near the gallbladder. In the axial plan (A) and (B)
the multiplanar reconstruction in the coronal plan, multidetector CT scan before microwave ablation (MWA) treatment during arte-
rial phase of contrast study; the lesion shows hyperenhancement. After MWA treatment (C and D), the lesion appears without
enhancement (arrow). No biliary complications are evident.
Table 2. Overall survival, local recurrence, complication rates, disease-free survival and mortality in patients with
hepatocellular carcinoma treated with microwave ablation (vs. radiofrequency ablation)
Study
OS; 1, 3, 5 yr OS
rates (vs. RF), %
Local recurrence
(vs. RF), %
Complications
rates (vs. RF), %
DFS; 1, 3, 5 yr OS
rates (vs. RF), %
Mortality
(vs. RF), %
Swan et al. [38] 72.8, –,– 2.9 28.9 22 mo 5
Liang et al. [39] – – 2.6 – 0.2
Lu et al. [43] 32.5 mo (vs. 27.1 mo) 11.8 (vs. 20.9) 8.2 (vs. 5.7) 15.5 mo (vs. 16.5 mo) 0 (vs. 0)
Simo et al. [45] – 7.7 (vs. 0) 61.5 (vs. 45.4) – 15 (vs. 36)
Ohmoto et al. [47] 14.3 (vs. 0) – –
1-yr 89 (vs. 100) 13 (vs. 9)
2-yr 70 (83) 16 (9)
3-yr 49 (vs. 70) 19 (vs. 9)
4-yr 39 (vs. 70) 19 (vs. 9)
Thornton et al. [49] – 5 (vs. 46.6) 10 (vs. 20) 14 mo (vs. 10.5 mo) –
Abdelaziz et al. [51] 17.8 (vs. 18.2) 2.2 (vs. 0) – –
Focal lesion ≤3 cm 50 mo (vs. 27 mo) 81.20 (vs. 70)
Focal lesion >3 cm 22 mo (vs. 21 mo) 65.10 (vs. 14)
Abbreviations: –, not applicable; DFS, disease-free survival; OS, overall survival; RF, radiofrequency.
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volumes were similar for Lap-RFA and Lap-MWA at 23.43 and
28.99 cm. Operative times were 149  35 min for Lap-RFA
and 112  40 min for Lap-MWA. Lap-RFA group had a mean
follow-up of 19 months: 50% were alive without disease evi-
dence, 9% were alive with disease, 36% died, and 5% were
lost to follow-up. The Lap-MWA group had a mean follow-up
of 7 months: 54% were alive without disease evidence, 31%
were alive with disease, and 15% died. Even if the safety of
Lap-MWA is similar to Lap-RFA, this procedure offers shorter
operative times and more complete necrosis rate [45].
Lesions located to VIII segment are often the most chal-
lenging to treat with laparoscopic or percutaneous method
because of cephalad location near the diaphragm (Fig. 3).
Because there was a 20% failure rate for lesions of segment
VIII, these patients are candidates for repeat ablation [46]. Abe
et al. described complete ablation of HCC lesions of segment
VIII in 9 of 15 lesions. In their cases, among the six lesions that
had incomplete necrosis, two were near the diaphragm. The
authors do not recommend MWA treatment for lesions that
are in contact with the diaphragm because there was an
increase of incomplete ablation risk, diaphragm injury, and
pneumothorax [46]. Additionally, the researchers showed that
the lesions near to the gallbladder are difficult for complete
coagulation to be achieved. Thus, the authors recommend
ablation in close proximity to the gallbladder be performed,
combining it with laparoscopic cholecystectomy. Conversely,
Simo et al. [45] used MWA for two segment IVB lesions that
were close to the gallbladder, and they obtained complete
necrosis without residual tumor or complications.
Ohmoto et al. assessed the therapeutic efficacy and safety of
RFA and percutaneous MWA to treat HCCs smaller than 2 cm in
diameter [47]. Thirty-seven HCCs in 34 patients were subjected to
RFA and compared with 56 HCCs (49 patients) that underwent to
MWA. The procedure was repeated until complete tumor abla-
tion. The efficacy and complications were compared between the
two approaches. There were significantly fewer treatment ses-
sions in the RFA group than in the MWA group, but the ablation
area was significantly larger in the former group. Regional recur-
rence rate was significantly lower with RFA than MWA, although
the ectopic recurrence percentage showed no significant differ-
ence. The cumulative OS was significantly higher for RFA than
MWA. The pain and fever incidence was significantly higher for
MWA than RFA. Bile duct injury, pleural effusion, and ascites were
also significantly more common after MWA [47].
Zanus et al. evaluated the macroscopic and microscopic evi-
dence of complete tumor ablation on explanted liver specimens
[48]. A total of 154 patients with HCC were treated with several
treatment approaches: percutaneous ablation (73 patients) for
114 nodules (mean size, 35.6  18.3 mm) was performed with
85 sessions; model for end-stage liver disease (MELD) score
was 9.3  2.6. Video-assisted laparoscopic ablation was per-
formed in 69 patients with 89 nodules and a mean size of
30.1  15.7 mm. Video-thoracoscopic ablation was successful
in three patients with posterior lesions located in an area
not otherwise treatable with a noninvasive technique, and
open ablation was performed in nine patients combined with
other laparotomy resection procedures. Six patients underwent
orthotopic liver transplantation (OLT) with cava-preserving tech-
nique. Two patients were subjected to MWA downstaging with
return to OLT criteria after ablative treatment; four patients
were subjected to MWA while awaiting OLT, seeking to reduce
the list dropout risk. Independently of the procedure (percuta-
neously or laparoscopically), the specimens showed resolution
of treated nodules by histological findings without peritoneal
carcinomatosis and lymph node involvement at the time of
OLT. According to Zanus et al. [48], MWA appeared to be a safe
procedure to treat unresectable HCC. The technological pro-
gress (“mini-choke”) permits researchers to obtain a larger
diameter of necrosis area more quickly than with RFA [48].
Thornton et al. compared the initial response, local recurrence,
and complication rates of RFA versus MWA when combined
with neoadjuvant bland transarterial embolization (TAE) or
drug-eluting microsphere chemoembolization (TACE) for the
treatment of HCC [49]. Thirty-five patients with HCC with
Barcelona Clinic Liver Cancer (BCLC) very early and early stage
(range, 1.2–4.1 cm) underwent TAE (23), TACE (12), RFA (15),
or MWA (20). Complete response rate was 80% (12/15) for
RFA + TAE/TACE and 95% (19/20) for MWA + TAE/TACE. Local
recurrence rate was 30% (4/12) for RFA + TAE/TACE and 0%
(0/19) for MWA + TAE/TACE. Durability of response, defined
as local disease control for the duration of the study, demon-
strated a significant difference in favor of MWA. There was no
statistical difference in complication rates (3% vs. 2%) [49]. In
contrast to Thornton et al. [49], Vasnani also compared the
efficacy of RFA and MWA in combination with transarterial
chemoembolization (DEB-TACE), demonstrating that both RFA
and MWA in sequential combination with DEB-TACE are
equally efficacious at inducing HCC tumor coagulation [50].
Figure 3. A 62-year-old man with hepatocellular carcinoma on VIII hepatic segment. Post- microwave ablation (MWA) treatment
Multidetector CT scan [(A) arterial phase of contrast study] and magnetic resonance imaging study [(B) volume-interpolated
breath-hold examination T1 weigthed fat sat during arterial phase of contrast study]. The lesion shows no contrast enhancement,
with hypodense (A) and hypointense signal compared with surrounding liver parenchymal (arrow).
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The authors assessed 42 patients who underwent combined
therapy: 11 tumors (2.9 cm; range, 1.8–4.3) treated with DEB-
TACE/RFA and 40 tumors (mean, 2.4 cm; range, 1.1–5.4) with
DEB-TACE/MWA. The mean TACE sessions in the RFA and
MWA groups were 1.3 (range, 1–2) and 1.3 (range, 1–3),
respectively. The mean thermal ablations in the RFA and
MWA groups were 1.2 (range, 1–2) and 1.3 (range, 1–3),
respectively. Tumor necrosis was assessed on explanted livers.
For RFA and MWA groups, necrosis was of 88.9% (range, 0%–
100%) and of 90.5% (range, 30%–100%), respectively. Com-
plete tumor coagulation percentage for RFA and MWA was of
45% and of 53%, respectively. No difference in tumor necrosis
was found between the two groups when tumors <3 cm
and >3 cm were considered separately. Among all 51 tumors,
mean tumor coagulation of 95.8% was found on the 36 com-
plete response on imaging at liver transplantation (LT). No cor-
relation was reported between tumor coagulation and initial
tumor size or time interval to LT. No tumor seeding was dem-
onstrated along the ablation tracts [50]. Abdelaziz et al. dem-
onstrated that TACE-MWA obtained better response rates
than TACE-RFA with tumor size of 3–5 cm, with no difference
in survival rates [51]. They assessed 22 patients who
underwent TACE-RFA and 45 who underwent TACE-MWA. All
patients were classified as Child-Pugh class A/B cirrhotics, and
no lesion was larger than 5 cm in diameter. TACE was followed
within 2 weeks by either RFA or MWA. The TACE-MWA group
had a higher complete response rates than TACE-RFA group.
This was mainly apparent with lesions size of 3–5 cm. The
researchers showed that there were no significant difference
of rates of complications between the groups, as well as the
recurrence-free survival (RFS) at 1- year, 2-, and 3- years (for
the TACE-RFA group, 70%, 42%, and 14%, respectively and for
TACE-MWA group, 81.2%, 65.1%, and 15.1%). Overall median
survival was 27 months. In relation to the size of focal lesions,
they found no statistically significant difference in the survival
proportions between the groups [51].
Yi et al. compared RFA or MWA and TACE with RFA or
MWAmonotherapy in HCC. They enrolled 94 patients with HCC
≤7 cm who were randomly allocated into the combined treat-
ment group (TACE-RFA or TACE-MWA) and control group (RFA
alone or MWA alone). The primary objective was OS. The sec-
ondary objective was recurrence-free survival, and the tertiary
objective was adverse effects. Seventeen patients in the com-
bined group died at the time of the report (median follow-up
time was 47.5 11.3 months). Twenty-five patients in the con-
trol groupdied (median follow-up timewas47.0 12.9months).
The researchers showed that the patients in the TACE-RFA or
TACE-MWA group had better OS than the RFA or MWA. In fact,
the 1-, 3-, and 5-year OS for the TACE-RFA or TACE-MWA group
were 93.6%, 68.1%, and 61.7%, respectively, whereas for the
RFA or MWA, the rates were 85.1%, 59.6%, and 44.7%, respec-
tively. Also, they showed that the combined group had a better
RFS than RFA or MWA. They concluded that RFA or MWA com-
bined with TACE to treat HCC lesions ≤7 cm was superior to
RFA or MWA alone [52]. In fact, iodized oil and gelatin sponge
particles used in TACE can increase RFA- or MWA-induced coag-
ulation necrosis by going through multiple arterio-portal com-
munications, and effects are improved in terms of shorter
ablation time, maximum output, and portal angiography by
TACE with iodized oil. Several authors showed that recurrent
lesions usually arose in the liver at a segment distant from re-
section margin or at multiple liver segments [53, 54]. Therefore,
TACE, thanks to the possibility of creating an enlarged ablated
area, gives better control on microlesions and increases the
chance of total necrosis of satellite nodules, reducing the risk of
recrrence, and improving patients outcomes [55].
RFA is now the most common and extensively employed
ablation therapy. It had several advantages, such as safety,
tolerability, efficacy, ease of use, and cost-effectiveness.
Several studies showed that RFA, among all ablative proce-
dures, is to be chosen in patients with HCC smaller than
3 cm, because it reported a complete necrosis frequency of
99% of treated lesions [56]. A large number of studies have
confirmed the efficacy of RFA in patients with early HCC,
suggesting this procedure as feasible therapeutic option in
unresectable early stage. Considering the state of the art of
the literature, RFA provided 5-year survival rates of 40%–
70% and beyond in HCC series [27–36]. However, despite
the high rate of necrosis, the recurrence frequency is
extremely variable, from 2% to 39% [27–36]. Unlike OS,
reported rates of LR after RFA are not univocally ranging
[27–36], maybe because of different etiologies of HCC in
the published series, different approaches to the problem
of insufficient ablative margins, use of combined treatment
and, above all, different definition of radiologic tumor
recurrence at imaging. Moreover, an insufficient ablation
margin after the treatment appear to be an important prog-
nostic factor for LR. The main limits of RFA are associated
with poor energy penetration into tissues with high thermal
and electric impedance, the intrinsic 100C upper temperature
threshold that causes tissue charring, and the slow tissue
heating mechanism leading to tissue sensitivity to convective
heat-sink effects induced by blood circulation in proximity to
the ablation area. MWA exceeds all these limits. However,
higher heating velocity and efficacy are achieved through a
somewhat increased technological complexity, and costs com-
pared with RFA [57]. Early MWA systems had some technical
limits, such as inadequate power handling to large probe
diameter, poor predictability of the radiated field pattern, and
uncontrolled back-heating effects. MW devices upgrade
allowed treatment of medium and large HCC lesions through a
percutaneous or laparoscopic approach. Therefore, hepatic
nodules close to gallbladder, bile ducts, or gastrointestinal tract
could be safely treated in this way. Laparoscopic MWA can also
be a feasible choice for patients unsuitable for HR because of
impaired liver function or severe comorbidities [57].
A large number of studies have confirmed the
efficacy of RFA in patients with early HCC, suggesting
this procedure as feasible therapeutic option in
unresectable early stage. Considering the state of
the art of the literature, RFA provided 5-year survival
rates of 40%–70% and beyond in HCC series.
The major open question is related to the optimal size range
of liver tumors amenable to ablation therapy, which has not
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been clearly defined and is closely related to anatomic fac-
tors, such as proximity to major vessels that influence the
ability to deposit sufficient thermal dose to coagulate tissue.
Likewise, the number of tumors in a single patient that can
undergo ablation is difficult to specify because the size of
each tumor will also play a role in effectiveness. Although
there is no established threshold of tumor diameter or tumor
number that is associated with ablation treatment success or
failure, our current understanding of hepatic tumor ablation
indicates that HCCs 5 cm or less in diameter have a higher
probability of having complete ablation compared with those
greater than 5 cm in diameter. Indeed, this size stratification
has been taken further to show superior results with tumors
smaller than 3 cm, intermediate but acceptable results for
those measuring 3–5 cm, and fairly dismal results for tumors
larger than 5 cm [26].
Metastases and Ablative Techniques
The increase of knowledge in oncology and the necessity to
manage patients with metastatic disease within a multi-
disciplinary team has improved the clinical outcome [58]. In
fact, today the median OS frequency for patients with met-
astatic colorectal cancer is 30 months, more than double
that of 20 years ago; the features involved are a closer
patient follow-up to obtain an earlier detection of meta-
static disease, efficacy increase of systemic therapies based
on patient selection, and an increase in the number of
patients undergoing complete surgical resection of metasta-
ses [59]. Additionally, the spread of ablative techniques [60]
and of chemotherapeutic targeted therapies [61, 62] can be
selectively applied with the aim to make the patient eligible
for resection. Although surgical resection is still the gold
standard for the management of metastatic liver cancer,
most patients are not eligible for this procedure because of
anatomic limitations, insufficient functional liver reserve,
multifocal nature of the disease, extrahepatic metastases,
or medical comorbidities [63]. Consequently, several abla-
tive or interstitial therapies have been developed for the
treatment of unresectable liver metastases.
Metastases and RFA
RFA has become a recognized therapy because of its efficacy,
safety, and availability [58]. However, major limits are high
local recurrence frequencies (Fig. 4), mainly for lesions larger
than 3 cm [64, 65], and a potential incomplete ablation of
lesion near large vessels (>3 mm in diameter). In this setting,
multiple overlapping probe placements are required to
achieve larger ablation zones, which makes the procedure
more consuming and less safe for the patient [65]. Therefore,
technological progresses resulted in the development of new
ablative techniques such as the MW (Table 3).
Metastases and MWA
MWA energy is not limited by charring and tissue desiccation,
whereas the size and shape of the ablation zone may be more
consistent and less dependent on the heat-sink effect (Fig. 5)
[8–10]. MWA zone can be up to 6 cm surrounding the MW
antenna, allowing for a large cell destruction volume within the
targeted area [66–68]. Size and geometry of the ablated area
are further features from which depend local recurrence after
ablative treatment. Studies on the ablated area size after MWA
versus RFA are contradictory, as little is known about the
ablated zone geometry [69, 70]. Several authors demonstrated
that larger necrosis area can be obtained with multiple or clus-
tered MW antennas [71–73]. In fact, using simultaneous
multiple-probe MWA, it is possible to obtain more uniform
necrosis area with a better performance near blood vessels that
might decrease recurrence rates after treatment. However, the
use of multiple-probe MWA could cause an increased “comet
effect” and unwanted collateral damage to neighboring struc-
tures [74]. Conversely for tumors with dimeter <2.0 cm, one or
two deployments of the RF monopolar multiple array needle
electrode are sufficient to produce complete tumor necrosis.
However, with increasing tumor size, there is an increase in the
number of RF needle electrode deployments and in the time to
produce complete coagulative necrosis. Generally, RFA is a safe,
well-tolerated, effective treatment for unresectable hepatic
malignancies with a dimeter <6.0 cm [75]. Velez et al. assessed
the safety and efficacy of ablative therapies in preclinical study
on F344 rats (150 g, n = 96) with subcutaneous R3230 breast
adenocarcinoma tumors, testing the device effect and
heating parameters on local tissue reactions and distant
tumor growth [76]. They evaluated RFA (70C for
5 minutes), rapid higher-powerMWA (20W for 15 seconds),
slower lower-power MWA (5 W for 2 minutes), or a sham
procedure (needle placement without energy). The rats
were sacrificed at 6 hours and up to 7 days. Distant tumor
growth frequencies were determined to 7 days after
Figure 4. A 48-year-old woman with colorectal liver metastasis on VI hepatic segment treated with radiofrequency ablation. In (A)
(Multiplanar reconstruction in coronal plane) and (B) (Multidetector CT in axial plane during portal phase of contrast study), incom-
plete ablation with residual disease (arrow) that shows less hypodense feature compared with ablated zone.
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treatment. They assessed liver heat shock protein (HSP)
70 levels (at 72 hours) and macrophages (CD68 at 7 days),
tumor proliferative indexes (Ki-67 and CD34 at 7 days), and
serum and tissue levels of interleukin 6 (IL-6) at 6 hours,
hepatocyte growth factor (HGF) at 72 hours, and vascular
endothelial growth factor (VEGF) at 72 hours. At 7 days,
they showed that 5-W MWA and RFA amplified distant
tumor size than to 20-WMWA and the sham procedure RFA
and 5-W MWA improved postablation tumor growth pro-
portions compared with the 20-W MWA and sham arms.
Tumor proliferation (Ki-67 percentage) was increased for 5-W
MWA (82%  5) and RFA (79%  5), followed by 20-W MWA
(65% 2), compared with sham (49% 5). Also, distant tumor
microvascular density was greater for 5-W MWA and RFA. Fur-
thermore, 5-MWA and RFA resulted in increased HSP 70 expres-
sion and macrophages in the peri-ablational rim. Last, IL-6, HGF,
and VEGF elevations were seen in 5-WMWA and RFA compared
with 20-WMWA and sham. They concluded that althoughMWA
can cause peri-ablation inflammation and increased distant
tumor growth similar to RFA in an animal tumor model, higher-
power, faster heating protocols might theoretically reduce unde-
sired effects [76].
Figure 5. A 51-year-old man with colorectal liver metastasis. Magnetic resonance imaging [(A) VIBE T1-W FS during portal phase of
contrast study and (B) Multiplanar reconstruction in coronal plane] and multidetector CT [(C) portal phase of contrast study on axial
plane and (D) MPR in coronal plane] studies show lesion without enhancement, with regular enhancement of portal branch near to
the treated area. The time between the MDCT examination and MR scan is 7–10 days.
Table 3. Overall survival, local recurrence, complication rates, disease-free survival, and mortality in liver metastases
patients treated with RFA or MWA
Study
OS
1, 3, 5 yr OS rates,
RFA (vs. MWA)
Local
recurrence,
RFA (vs. MWA)
Complications
rates,
RFA (vs. MWA)
DFS
1, 3, 5 yr OS
rates, RFA
(vs. MWA)
Mortality,
RFA
(vs. MWA)
Scaife et al. [60] – 10 22 – 2
van Duijnhoven
et al. [64]
27.8 mo 35.7 – 15 mo –
van Tilborg et al.
[77]
not statistically different
for both the survival
times from primary tumor
diagnosis and survival
times from ablation
3 mo, 9.3 and 12 mo,
21.9 (vs. 25.0 and 39.6)
3.2 (vs. 57.1) – 0 (vs. 0)
Correa-Gallego
et al. [79]
no difference (55 mo [IQR
25-NR] vs. NR [IQR 25-NR]
for RFA and MWA,
respectively, p = .5)
20 (vs. 6) 24 (vs. 27) – –
Liu et al. [81] 84.9, 48.8, 36.3 20.3 (vs. 8.6) 1.1; no difference – 0 (vs. 0)
Ding et al. [87] – – 3.5 (vs. 3.1) – 0.31 (vs. 0.36)
Abbreviations: –, not applicable; DFS, disease-free survival; MWA, microwave ablation; mo, months; NR, not appropriate; OS, overall survival;
RFA, radiofrequency ablation; yr, year.
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A paper by van Tilborg et al. reported RFA and MWA
safety and efficacy in the treatment of unresectable colo-
rectal liver metastases (CRLMs) near large vessels and/or
major bile ducts. It is known that heat could cause acute
or chronic damage to major bile ducts. Although MWA in
several preclinical and clinical studies has been suggested
to be more effective than RFA for perivascular nodules
[20, 21, 23–25], the authors showed that for perivascular
CRLM, RFA and MWA are both safe options that effective
treatments. MWA is currently supported as superior to
RFA for perivascular lesions, whereas RFA represent a
safer option for peribiliary CRLM because of the less
aggressive heat production and superior ablation zone
predictability (Fig. 6). The authors evaluated 243 patients
with 774 unresectable CRLM. One hundred and twenty-
two patients had at least one perivascular or peribiliary
lesion (n = 199). Primary efficacy rate of RFA was superior
to MWA after 3 and 12 months of follow-up; however,
after multivariate analysis, this difference was nonsignifi-
cant at 12 months and disappeared after repeat ablations
[77]. Complications were classified according to the con-
ventional criteria for adverse events (CTCAE version 4.0)
and divided into three categories: (a) electrode or antenna
placement, (b) thermal injury, and (c) secondary to the
general procedure [78]. More CTCAE grade III complica-
tions happened after MWA versus RFA (18.8 vs. 7.9 %).
Thermal ablation near to major bile ducts appears effec-
tive, although major complications can occur. Similar effi-
cacy and lower complication rates were demonstrated for
RFA in lesions that are located in the vicinity of the main
bile ducts [77].
Contrary to van Tilborg et al. [77], Correa-Gallego et al. [79]
demonstrated that MWA is more effective than RFA, with a
decrease in local recurrence rate. They treated 351 tumors
(222 RFA and 129 MWA). Twenty-five percent of patients
showed post-treatment complications. The researchers showed
that the morbidity rates were similar between the MWA and
RFA group (27% vs. 24 %, respectively). Regional recurrence
was seen in 19% of cases. MWA group had lower recurrence
rates compared with RFA group, whereas follow-up time was
significantly shorter for MWA group (18 months) than RFA
group (31 months). There was no difference between groups in
median values of OS [79].
In a recent systematic review (75 studies enrolled; years
range between 1994 and 2010), the authors evaluated clini-
cal outcomes and local recurrence rates postablative thera-
pies in colorectal liver metastases. They showed that RFA
had regional recurrence rates (between 10% and 31%)
lower than cryotherapy (12%–39%). MWA showed the low-
est regional recurrence percentages (5%–13%). These publi-
cations cover a long time period, during which the criteria
to define resectable a hepatic lesion have changed dramati-
cally, thus making a comparison between these cohort stud-
ies intrinsically flawed [80].
Liu et al. assessed the RFA and MWA efficacy and safety
not only in colorectal metastases [81]. One hundred and
thirty-two liver metastases in 89 patients (size, 0.8–5.0 cm)
were treated with MWA or RFA. Local tumor control, com-
plications, and long-term survival were analyzed. MWA
resulted in less local recurrence than RFA. Complete necro-
sis was relived in 117 of 132 (88.6%) nodules. Local recur-
rence was relived in 17 of 117 (14.5%) nodules. A
Figure 6. A 72-year-old woman with peribiliary colorectal liver metastasis treated with microwave ablation. Magnetic resonance
imaging [(A) half-Fourier acquired single-shot turbo spineEcho T2 weighted coronal plane; (B) T1-W in of phase in axial plane; (C)
T1-W out of phase in axial plane; (D) volume-interpolated breath-hold examination T1 weigthed fat sat during arterial phase of con-
trast study; (E) VIBE T1-W FS during portal phase of contrast study] study shows the lesion with hypointense signal on T2-W,
hypointense signal on T1-W (B and C), without contrast enhancement (D and E) and with biliary injury (dilation of a biliary branch;
arrows).
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significant trend toward a lower local recurrence rate with
MWA was observed. Multivariate analysis indicated that
the number of cycles of chemotherapy was the significant
prognostic factor for overall recurrence, whereas disease-
free interval was the significant prognostic factor for distant
recurrence. Ablation modality showed potential prognostic
significance for regional recurrence. Major complications
occurred in 1.1% of patients. The 1-, 2-, 3-, and 5-year OS
were 84.9%, 59.6%, 48.8%, and 36.3%, respectively [81].
The efficacy and limits of RFA for liver metastases have
widely been reported. Because of the physical limits in
energy penetration, the RFA efficacy in local tumor control
decreases increasing lesion size, so the site close to large
vessels can influence the effectiveness as previously
reported. As is reported for HCC, in the treatment of metas-
tases, MWA causes larger ablation areas than RFA and
appears to be less influenced by heat-sink effect. Several
studies showed that outcomes of RFA and MWA in patients
with up to six metastases (with dimeter <6 cm) are compa-
rable, with 3-year OS of 28%–46% and 46%–51%, respec-
tively, and 5-year OS of 25%–46% and 17%–32%,
respectively [82, 83].
According to the literature, the overall survival, local
recurrence, complication rates, and mortality in patients
with liver metastases treated with RFA (vs. MWA) are not
statistically different for both the survival times from pri-
mary tumor diagnosis and survival times from ablation,
between 10% (vs. 6%) and 35.7% (vs. 39.6), between 1.1%
(vs. 3.1%) and 24% (vs. 27%), and between 0% (vs. 0%) and
2% (vs. 0.3%).
To date, in most centers of interventional oncology or
interventional radiology, the procedure choice depends on
the physician’s experience or technical availability. However,
these techniques have specific advantages and limitations
that can make each of them more appropriate than the
other one to treat patients with different characteristics.
RFA is the longer recognized ablative technique, and its effi-
cacy has been largely proven; subcapsular or high-risk loca-
tion of the tumors is considered a relative contraindication
to RFA, so, as lesions from >2 to 2.5 cm, need multiple over-
lapping ablations to obtain a complete necrosis. This is also
the case if tumors close to large blood vessels can be
incompletely treated because of the heat-sink effect. MWA
can cause necrosis in a larger target area; has deeper pene-
tration of energy, with better propagation across the poorly
conductive tissue; and shows less sensitivity to heat-sink
effect than RFA. In contrast, MW energy is more difficult to
distribute than RF energy [11]. Consequently, MWA appears
less feasible than RFA in the treatment of high-risk located
and subcapsular nodules. Also, the cost of the procedure
could be considerate during the work up of the patient. In
fact, the cost of MW antennas in the U.S. is about $3,000,
whereas the RFA probes are much less; conversely, in
Europe the costs are similar, with a difference of about
500 Euros. Some authors suggest that the reference centers
for thermal ablation should be equipped with all available
procedures so as to be able to use the best and the most
suitable one for each type of tumor [84]. Recently,
according to advantages and limits of the different ablative
techniques, and to the number, size, and location of the
liver lesions and cost-saving considerations, an algorithm
has been proposed [85]. On the basis of this algorithm, a
single nodule <2 cm in size could be treated using all the
thermal procedures, but RFA and laser thermal ablation
Figure 7. A 72-year-old man with microwave ablated colorectal liver metastasis (CRLM) on VIII-VII hepatic segment. Magnetic reso-
nance imaging [(A) volume-interpolated breath-hold examination T1 weigthed fat sat during arterial phase of contrast study in axial
plane; (B) volume-interpolated breath-hold examination T1 weigthed fat sat during portal phase of contrast study in axial plane; (C)
volume-interpolated breath-hold examination T1 weigthed fat sat during portal phase of contrast study in coronal plane] study
shows no residual disease and no diaphragm injury and pneumothorax. In (D) Multidetector CT scan during portal phase of contrast
study follow-up at 1 years post a new microwave ablation treatment for another CRLM: no residual disease and no diaphragm
injury and pneumothorax.
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(LTA) are cheaper than MWA and should be preferred. Con-
versely, MWA should be preferred in case of tumor size
≥3 cm in diameter (Fig. 7) or in case of large vessels close
to lesion independently by its size. LTA should be preferred
in case of multiple small and variably sized lesions. This
algorithm reflects the personal experience and opinion of
the authors [84].
COMPLICATIONS
Goldberg et al. defined a major complication as an event that
leads to substantial morbidity and disability, increasing the level
of care or resulting in hospital admission or substantially
lengthened hospital stay. Events different from this scenario are
minor complications [86]. To date, RFA and MWA do not show
statistically significant difference in mortality or major or minor
complications rates (Table 4) [87]. Specifically, MWA is a safe
technique for the treatment of unresectable liver tumors with a
mortality that ranges from 0% to 0.36% [88–91]. RFA and MWA
have the same rate of major complications [88–91]. To reduce
major complications incidence (Fig. 8), the patient selection and
percutaneous or surgical approach choice are essential; high-risk
patients for infections, coagulation disorders, and previous
abdominal surgery should be evaluated to establish the right
cost-benefit rate of the ablation method. Gastrointestinal perfo-
ration or thermal biliary injury should be avoided using
Table 4. Mayor complication rates, minor complication rates and mortality in liver tumor treated with RFA or MWA
Study Technique Mayor complication rates, % Minor complication rates, % Mortality, %
Park et al. [27] RFA 10.5 – 0
Gory et al. [31] RFA 2 – –
Swan et al. [38] MWA 28.9 – 5
Liang et al. [39] MWA 2.6 – 0.2
Lu et al. [43] MWA/RFA 8.2/5.7 – 0/0
Simo et al. [45] MWA/RFA 61.5/45.4 – 15/36
Ohmoto et al. [47] MWA/RFA 14.3/ 0 – –
Thornton et al. [49] MWA/RFA 10/20 – –
Abdelaziz et al. [51] MWA/RFA 2.2/0 – –
Scaife et al. [60] RFA 22 2
Simon et al. [73] MWA No direct post-treatment
complications were noted
– 5 related to hepatic
resection
van Tilborg et al. [77] RFA/MWA 3.2 /57.1 0/0
Gillams et al. [82] RFA 4 6 –
Ding et al. [87] RFA/MWA 3.5/3.1 0.31/0.36
Liang et al. [89] MWA 2.6 100 0.2
Livraghi et al. [90] MWA 2.9 7.3 0
Abbreviations: –, not applicable; MWA, microwave ablation; RFA, radiofrequency ablation.
Figure 8. Multidetector CT scan without contrast medium during emergency setting (A and B) for hemoperitoneum post-
radiofrequency ablation treatment. The bleeding is hyperdense (arrow).
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thermocouples to check the temperature and allow timely pro-
cedure interruption. Moreover, physicians learning curve and
MW antenna technology progress have considerably reduced
complications from thermal damage [91].
RFA and MWA do not show statistically significant
difference in mortality or major or minor complica-
tions rates (Table 4). Specifically, MWA is a safe
technique for the treatment of unresectable liver
tumorswithamortality that ranges from0%to0.36%.
RFA and MWA has the same rate of major complica-
tions. To reduce major complications incidence
(Fig. 8), the patient selection and percutaneous or
surgical approachchoiceareessential; high-riskpatients
for infections, coagulation disorders, and previous
abdominal surgery should be evaluated to establish
the right cost-benefit rate of the ablation method.
CONCLUSION
Surgical resection is the gold standard for treatment of pri-
mary or metastatic liver cancer. However, most patients are
not candidates for hepatic resection because of anatomic
limitations, multifocal nature of the disease, insufficient
functional liver reserve, extrahepatic metastases, or com-
orbidities. The most commonly used thermal ablation
modalities are RFA and MWA. RFA has become a recog-
nized treatment approach because of its efficacy, reproduc-
ibility, low complication rates, and availability. According to
the literature, the overall survival, local recurrence, compli-
cation rates, disease-free survival, and mortality in patients
with HCC treated with RFA vary between 53.2  3.0 months
and 66 months, between 59.8% and 63.1%, between
2% and 10.5%, between 22.0  2.6 months and 39 months,
and 0% and 1.2%, respectively. However, despite the high
rate of necrosis, the recurrence frequency is extremely
variable. Unlike OS, reported rates of LR after RFA are not
univocal ranging. The benefits of MWA are an improved
convection profile, higher constant intratumoral tempera-
tures, faster ablation times, and the ability to use multiple
probes to treat multiple lesions simultaneously. MWA target
area size and shape may be more consistent and less depen-
dent on the heat-sink effect from vascular structures in prox-
imity of the lesion. RFA has been available used in the time
and is the more established thermal technique, but lesions
with a diameter >2–2.5 cm need multiple overlapping
ablations, and subcapsular or high-risk location of tumors is
considered a relative contraindication to RFA. MWA should
be preferred when tumor size is ≥3 cm in diameter or in case
of lesion near to large vessels independently of size, More-
over, MWA can reach larger ablation volumes without heat-
sink effect. According to the literature, overall survival, local
recurrence, complication rates, disease-free survival, and
mortality in patients with HCC treated with MWA (compared
with RFA) vary between 22 months for focal lesion >3 cm
(vs. 21 months) and 50 months for focal lesion ≤3 cm
(vs. 27 months), between 5% (vs. 46.6%) and 17.8%
(vs. 18.2%), between 2.2 % (vs. 0%) and 61.5% (vs. 45.4%),
between 14 months (vs. 10.5 months) and 22 months (vs. no
data reported), and between 0% (vs. 0%) and 15% (vs. 36%),
respectively.
According to the literature, the overall survival, local
recurrence, complication rates, and mortality in patients
with liver metastases treated with RFA (vs. MWA) are not
statistically different for either the survival times from pri-
mary tumor diagnosis or survival times from ablation,
between 10% (vs. 6%) and 35.7% (vs. 39.6), between
1.1% (vs. 3.1%) and 24% (vs. 27%), and between 0%
(vs. 0%) and 2% (vs. 0.3%).
Therefore, the thermal ablation approach should depend
on patient characteristics. Reference centers for thermal abla-
tion should be equipped with all available techniques to be
able to use the best and the most suitable approach tailored
to each patient.
Regarding metastases, both RFA and MWA are safe options
for effective treatment. MWA is currently supported as superior
to RFA for perivascular lesions, whereas RFA represents a safer
option for peribiliary CRLM because of the less aggressive
heat production and superior ablation zone predictability.
ACKNOWLEDGMENTS
The authors are grateful to Alessandra Trocino, librarian at the
National Cancer Institute of Naples, Italy. Additionally, the
authors are grateful to Rita Guarino and Assunta Zazzaro for
their collaboration. The authors received no financial support
for the research, authorship, and/or publication of this article.
AUTHOR CONTRIBUTIONS
Conception/design: Vincenza Granata
Collection and/or assembly of data: Vincenza Granata, Roberto Grassi, Raffaele
Palaia, Paolo Delrio, Gianpaolo Carrafiello, Daniel Azoulay, Steven A Curley
Data analysis and interpretation: Roberta Fusco
Manuscript writing: Francesco Izzo, Vincenza Granata, Roberta Fusco,
Antonella Petrillo
Final approval of manuscript: Francesco Izzo, Vincenza Granata, Roberta
Fusco, Antonella Petrillo
DISCLOSURES
The authors indicated no financial relationships.
REFERENCES
1. Izzo F, Palaia R, Albino V et al. Hepatocellular
carcinoma and liver metastases: Clinical data on
a new dual-lumen catheter kit for surgical seal-
ant infusion to prevent perihepatic bleeding and
dissemination of cancer cells following biopsy
and loco-regional treatments. Infect Agent Can-
cer. 2015;10:11.
2. NCCN Clinical Practice Guidelines in Oncol-
ogy: Hepatobiliary Cancers. Version 2016. Fort
Washington, PA: National Comprehensive Cancer
Network, 2016.
3. European Association for Study of Liver;
European Organisation for Research and Treatment
of Cancer. EASL-EORTC clinical practice guidelines:
Management of hepatocellular carcinoma. Eur J
Cancer 2012;48(5):599–641.
4. Knavel EM, Brace CL. Tumor ablation: Com-
mon modalities and general practices. Tech Vasc
Interv Radiol 2013;16:192–200.
© AlphaMed Press 2019www.TheOncologist.com
Izzo, Granata, Grassi et al. e1003
5. Iannuccilli JD, Dupuy DE. How to set up a suc-
cessful tumor ablation practice. Tech Vasc Inter-
ventional Radiol 2013;16:201–208.
6. Gannon CJ, Curley SA. The role of focal liver
ablation in the treatment of unresectable primary
and secondary malignant liver tumors. Semin
Radiat Oncol 2005;15:265–272.
7. Garrean S, Hering J, Helton WS et al. A
primer on transarterial, chemical, and thermal
ablative therapies for hepatic tumors. Am J Surg
2007;194:79–88.
8. Andreano A, Huang Y, Meloni MF et al.
Microwaves create larger ablations than radio-
frequency when controlled for power in ex vivo
tissue. Med Phys 2010;37:2967–2973.
9. Lucchina N, Tsetis D, Ierardi AM et al. Current
role of microwave ablation in the treatment of
small hepatocellular carcinomas. Ann Gastroenterol
2016;29:460–465.
10. Brace CL. Radiofrequency and microwave
ablation of the liver, lung, kidney, and bone: What
are the differences? Curr Probl Diagn Radiol 2009;
38:135–143.
11. Crocetti L, de Baere T, Lencioni R. Quality
improvement guidelines for radiofrequency abla-
tion of liver tumours. Cardiovasc Intervent Radiol
2010;33:11–17.
12. Goldberg SN, Gazelle GS, Mueller PR. Thermal
ablation therapy for focal malignancy: A unified
approach to underlying principles, techniques, and
diagnostic imaging guidance. AJR Am J Roentgenol
2000;174:323–331.
13. Lencioni R, Crocetti L. Radiofrequency abla-
tion of liver cancer. Tech Vasc Interv Radiol 2007;
10:38–46.
14. Shimizu A, Ishizaka H, Awata S et al. Expan-
sion of radiofrequency ablation volume by satu-
rated NaCl saline injection in the area of
vaporization. Acta Radiol 2009;50:61–64.
15. Simon CJ, Dupuy DE, Mayo-Smith WW.
Microwave ablation: Principles and applications.
Radiographics 2005;25(suppl 1):69–83.
16. Tanaka M, Sato M. Microwave heating of
water, ice, and saline solution: Molecular dynam-
ics study. J Chem Phys 2007;126:034509.
17. Liang P, Yu J, Lu MD et al. Practice guide-
lines for ultrasound-guided percutaneous micro-
wave ablation for hepatic malignancy. World J
Gastroenterol 2013;19:5430–5438.
18. Sun Y, Wang Y, Ni X et al. Comparison of
ablation zone between 915- and 2,450-MHz
cooled-shaft microwave antenna: Results in vivo
porcine livers. AJR Am J Roentgenol 2009;192:
511–514.
19. Revel-Mouroz P, Otal P, Jaffro M et al.
Other non-surgical treatments for liver cancer.
Rep Pract Oncol Radiother 2017;22:181–192.
20. Yu N, Raman S, Kim Y et al. Microwave liver
ablation: Influence of hepatic vein size on heat-
sink effect in a porcine model. J Vasc Interv
Radiol 2008;19:1087–1092.
21. Lu D, Raman SS, Vodopich DJ et al. Effect of
vessel size on creation of hepatic radiofrequency
lesions in pigs: Assessment of the “heat sink”
effect. AJR Am J Roentgenol 2002;178:47–51.
22. Brannan J, Ladtkow C. Modeling bimodal
vessel effects on radio and microwave frequency
ablation zones. Conf Proc IEEE Eng Med Biol Soc
2009;2009:5989–5992.
23. Lu DS, Yu NC, Raman SS et al. Radio-
frequency ablation of hepatocellular carcinoma:
Treatment success as defined by histologic exam-
ination of the explanted liver. Radiology 2005;
234:954–960.
24. Shock SA, Meredith K, Warner TF et al.
Microwave ablation with loop antenna: In vivo
porcine liver model. Radiology 2004;231:143–9.
25. Carrafiello G, Laganà D, Mangini M et al.
Microwave tumors ablation: Principles, clinical
applications and review of preliminary experi-
ences. Int J Surg 2008;(suppl 1):S65–69.
26. Gervais DA, Goldberg SN, Brown DB et al.
Society of Interventional Radiology position
statement on percutaneous radiofrequency abla-
tion for the treatment of liver tumors. J Vasc
Interv Radiol 2009;20(suppl 7):S342–S347.
27. Park EK, Kim HJ, Kim CY et al. A comparison
between surgical resection and radiofrequency
ablation in the treatment of hepatocellular carci-
noma. Ann Surg Treat Res 2014;87:72–80.
28. Kim GA, Shim JH, Kim MJ et al. Radio-
frequency ablation as an alternative to hepatic
resection for single small hepatocellular carcino-
mas. Br J Surg 2016;103:126–135.
29. Liu PH, Hsu CY, Hsia CY et al. Surgical re-
section versus radiofrequency ablation for single
hepatocellular carcinoma ≤ 2 cm in a propensity
score model. Ann Surg 2016;263:538–545.
30. Wang JH, Wang CC, Hung CH et al. Survival
comparison between surgical resection and
radiofrequency ablation for patients in BCLC very
early/early stage hepatocellular carcinoma.
J Hepatol 2012;56:412–418.
31. Gory I, Fink M, Bell S et al.; Melbourne Liver
Group. Radiofrequency ablation versus re-
section for the treatment of early stage hepato-
cellular carcinoma: A multicenter Australian
study. Scand J Gastroenterol 2015;50:567–576.
32. Gavriilidis P, Askari A, Azoulay D. Survival
following redo hepatectomy vs radiofrequency
ablation for recurrent hepatocellular carcinoma:
A systematic review and meta-analysis. HPB
(Oxford) 2017;19:3–9.
33. Dong W, Zhang T, Wang ZG et al. Clinical
outcome of small hepatocellular carcinoma after
different treatments: A meta-analysis. World J
Gastroenterol 2014;20:10174–10182.
34. Hung AK, Guy J. Hepatocellular carcinoma
in the elderly: Meta-analysis and systematic liter-
ature review. World J Gastroenterol 2015;21:
12197–12210.
35. Salhab M, Canelo R. An overview of
evidence-based management of hepatocellular
carcinoma: A meta-analysis. J Cancer Res Ther
2011;7:463–475.
36. Mulier S, Ni Y, Jamart J et al. Local recur-
rence after hepatic radiofrequency coagulation:
Multivariate meta-analysis and review of contrib-
uting factors. Ann Surg 2005;242:158–171.
37. Baker EH, Thompson K, McKillop IH et al.
Operative microwave ablation for hepatocellular
carcinoma: A single center retrospective review
of 219 patients. J Gastrointest Oncol 2017;8:
337–346.
38. Swan RZ, Sindram D, Martinie JB et al. Opera-
tive microwave ablation for hepatocellular carci-
noma: Complications, recurrence, and long-term
outcomes. J Gastrointest Surg 2013;17:719–729.
39. Liang P, Wang Y, Yu X et al. Malignant liver
tumors: Treatment with percutaneous micro-
wave ablation—complications among cohort of
1136 patients. Radiology 2009;251:933–940.
40. Bertot LC, Sato M, Tateishi R et al. Mortality
and complication rates of percutaneous ablative
techniques for the treatment of liver tumors: A
systematic review. Eur Radiol 2011;21:2584–2596.
41. Ong SL, Gravante G, Metcalfe MS et al. Effi-
cacy and safety of microwave ablation for pri-
mary and secondary liver malignancies: A
systematic review. Eur J Gastroenterol Hepatol
2009;21:599–605.
42. Martin RC, Scoggins CR, McMasters KM.
Safety and efficacy of microwave ablation of
hepatic tumors: A prospective review of a 5year
experience. Ann Surg Oncol 2010;17:171–178.
43. Lu MD, Xu HX, Xie XY et al. Percutaneous
microwave and radiofrequency ablation for hepa-
tocellular carcinoma: A retrospective comparative
study. J Gastroenterol 2005;40:1054–1060.
44. Xu HX, Xie XY, Lu MD et al. Ultrasound-guided
percutaneous thermal ablation of hepatocellular
carcinoma using microwave and radiofrequency
ablation. Clin Radiol 2004;59:53–61.
45. Simo KA, Sereika SE, Newton KN et al. Laparo-
scopic-assisted microwave ablation for hepatocel-
lular carcinoma: Safety and efficacy in comparison
with radiofrequency ablation. J Surg Oncol 2011;
104:822–829.
46. Abe T, Shinzawa H,Wakabayashi H et al. Value
of laparoscopic microwave coagulation therapy for
hepatocellular carcinoma in relation to tumor size
and location. Endoscopy 2000;32:598–603.
47. Ohmoto K, Yoshioka N, Tomiyama Y et al.
Comparison of therapeutic effects between radio-
frequency ablation and percutaneous microwave
coagulation therapy for small hepatocellular carci-
nomas. J Gastroenterol Hepatol 2009;24:223–227.
48. Zanus G, Boetto R, Gringeri E et al. Micro-
wave thermal ablation for hepatocarcinoma: Six
liver transplantation cases. Transplant Proc 2011;
43:1091–1094.
49. Thornton LM, Cabrera R, Kapp M et al.
Radiofrequency vs microwave ablation after neo-
adjuvant transarterial bland and drug-eluting
microsphere chembolization for the treatment
of hepatocellular carcinoma. Curr Probl Diagn
Radiol 2017;46:402–409.
50. Vasnani R, Ginsburg M, Ahmed O et al.
Radiofrequency and microwave ablation in com-
bination with transarterial chemoembolization
induce equivalent histopathologic coagulation
necrosis in hepatocellular carcinoma patients
bridged to liver transplantation. Hepatobiliary
Surg Nutr 2016;5:225–233.
51. Abdelaziz AO, Abdelmaksoud AH, Nabeel MM
et al. Transarterial chemoembolization combined
with either radiofrequency or microwave ablation
in management of hepatocellular carcinoma. Asian
Pac J Cancer Prev 2017;18:189–194.
52. Yi Y, Zhang Y, Wei Q et al. Radiofrequency
ablation or microwave ablation combined with
transcatheter arterial chemoembolization in
treatment of hepatocellular carcinoma by com-
paring with radiofrequency ablation alone. Chin J
Cancer Res 2014;26:112–118.
53. Meniconi RL, Komatsu S, Perdigao F et al.
Recurrent hepatocellular carcinoma: A Western
strategy that emphasizes the impact of pathologic
© AlphaMed Press 2019
Radiofrequency Ablation and Microwave Ablatione1004
profile of the first resection. Surgery 2015;157:
454–462.
54. Marubashi S, Gotoh K, Akita H et al. Analysis
of recurrence patterns after anatomical or non-
anatomical resection for hepatocellular carci-
noma. Ann Surg Oncol 2015;22:2243–2252.
55. Shi M, Zhang CQ, Zhang YQ et al. Micro-
metastases of solitary hepatocellular carcinoma
and appropriate resection margin. World J Surg
2004;28:376–381.
56. Shiina S, Tateishi R, Arano T et al. Radio-
frequency ablation for hepatocellular carcinoma:
10-year outcome and prognostic factors.
Am J Gastroenterol 2012;107:569–577.
57. Poggi G, Tosoratti N, Montagna B et al.
Microwave ablation of hepatocellular carcinoma.
World J Hepatol 2015;7:2578–2589.
58. Van Cutsem E, Cervantes A, Adam R et al.
ESMO consensus guidelines for the management
of patients with metastatic colorectal cancer.
Ann Oncol 2016;27:1386–13422.
59. Izzo F, Piccirillo M, Palaia R et al. Manage-
ment of colorectal liver metastases in patients
with peritoneal carcinomatosis. J Surg Oncol
2009;100:345–347.
60. Scaife CL, Curley SA, Izzo F et al. Feasibility
of adjuvant hepatic arterial infusion of chemo-
therapy after radiofrequency ablation with or
without resection in patients with hepatic metas-
tases from colorectal cancer. Ann Surg Oncol
2003;10:348–354.
61. Fanotto V, Ongaro E, Rihawi K et al. HER-2
inhibition in gastric and colorectal cancers: Tangi-
ble achievements, novel acquisitions and future
perspectives. Oncotarget 201618;7:69060–69074.
62. Rosati G, Cordio S, Aprile G et al. Discontin-
uation of bevacizumab and FOLFIRI administered
up to a maximum of 12 cycles as first-line ther-
apy for metastatic colorectal cancer: A retrospec-
tive Italian study. Invest New Drugs 2012;30:
1978–1983.
63. Izzo F. Other thermal ablation techniques:
Microwave and interstitial laser ablation of liver
tumors. Ann Surg Oncol 2003;10:491–497.
64. van Duijnhoven FH, Jansen MC,
Junggeburt JM et al. Factors influencing the local
failure rate of radiofrequency ablation of colorectal
liver metastases. Ann Surg Oncol 2006;13:651–658.
65. Kim SK, Rhim H, Kim YS et al. Radiofrequency
thermal ablation of hepatic tumors: Pitfalls and
challenges. Abdom Imaging 2005;30:727–733.
66. Skinner MG, Iizuka MN, Kolios MC et al. A
theoretical comparison of energy sources – micro-
wave, ultrasound and laser – for interstitial thermal
therapy. Phys Med Biol 1998;43:3535–3547.
67. Strickland AD, Clegg PJ, Cronin NJ et al. Exper-
imental study of large-volume microwave ablation
in the liver. Br J Surg 2002;89:1003–1007.
68. Strickland AD, Clegg PJ, Cronin Nj et al.
Rapid microwave ablation of large hepatocellular
carcinoma in a high-risk patient. Asian J Surg
2005;28:151–115.
69. Wright AS, Sampson LA,Warner TF et al. Radio-
frequency versus microwave ablation in a hepatic
porcinemodel. Radiology 2005;23:132–139.
70. Shibata T, Npinobu T, Ogata N. Comparison of
the effects of in-vivo thermal ablation of pig liver
by microwave and radiofrequency coagulation.
J Hepatobiliary Pancreat Surg 2000;7:592–598.
71. Hines-Peralta AU, Pirani N, Clegg P et al.
Microwave ablation: Results with a 2.45-GHz
applicator in ex vivo bovine and in vivo porcine
liver. Radiology 2006;239:94–102.
72. Meredith K, Lee F, Henry MB et al. Micro-
wave ablation of hepatic tumors using dual-loop
probes: Results of a phase I clinical trial.
J Gastrointest Surg 2005;9:1354–1360.
73. Simon CJ, Dupuy DE, Iannitti DA et al.
Intraoperative triple antenna hepatic microwave
ablation. AJR Am J Roentgenol 2006;187:W333–340.
74. Wright AS, Lee FT Jr, Mahvi DM. Hepatic
microwave ablation with multiple antennae
results in synergistically larger zones of coagula-
tion necrosis. Ann Surg Oncol 2003;10:275–283.
75. Curley SA. Radiofrequency ablation of malig-
nant liver tumors. The Oncologist 2001;6:14–23.
76. Velez E, Goldberg SN, Kumar G et al. Hepatic
thermal ablation: Effect of device and heating
parameters on local tissue reactions and distant
tumor growth. Radiology 2016;281:782–792.
77. van Tilborg AA, Scheffer HJ, de Jong MC
et al. MWA versus RFA for perivascular and per-
ibiliary CRLM: A retrospective patient- and
lesion-based analysis of two historical cohorts.
Cardiovasc Intervent Radiol 2016;39:1438–1446.
78. National Cancer Institute. Common Termi-
nology Criteria for Adverse Events v.3.0 and
v.4.0 (CTCAE). http://ctep.cancer.gov/protocol
Development/electronic_applications/ctc.htm.
Accessed June 14, 2011.
79. Correa-Gallego C, Fong Y, Gonen M et al. A
retrospective comparison of microwave ablation
vs. radiofrequency ablation for colorectal cancer
hepatic metastases. Ann Surg Oncol 2014;21:
4278–4283.
80. Pathak S, Jones R, Tang JM et al. Ablative
therapies for colorectal liver metastases: A system-
atic review. Colorectal Dis 2011;13:e252–e265.
81. Liu Y, Li S, Wan X et al. Efficacy and safety of
thermal ablation in patients with liver metastases.
Eur J Gastroenterol Hepatol 2013;25:442–446.
82. Gillams AR, Lees WR. Radiofrequency abla-
tion of colorectal liver metastases. Abdom Imag-
ing 2005;30:419–426.
83. Tanaka K, Shimada H, Nagano Y et al. Out-
come after hepatic resection versus combined
resection and microwave ablation for multiple
bilobar colorectal metastases to the liver. Surgery
2006;139:263–273.
84. Sartori S, Di Vece F, Ermili F et al. Laser
ablation of liver tumors: An ancillary technique,
or an alternative to radiofrequency and micro-
wave? World J Radiol 2017;9:91–96.
85. Tombesi P, Di Vece F, Sartori S. Radio-
frequency, microwave, and laser ablation of liver
tumors: Time to move toward a tailored ablation
technique? Hepatoma Res 2015;1:52–57.
86. Goldberg SN, Grassi CJ, Cardella JF et al.
Image-guided tumor ablation: Standardization of
terminology and reporting criteria. J Vasc Interv
Radiol 2009;20(suppl 7):S377–S390.
87. Ding J, Jing X, Liu J et al. Complications of
thermal ablation of hepatic tumours: Compari-
son of radiofrequency and microwave ablative
techniques. Clin Radiol 2013;68:608–615.
88. Bertot LC, Sato M, Tateishi R et al. Mortality
and complication rates of percutaneous ablative
techniques for the treatment of liver tumors: A
systematic review. Eur Radiol 2011;21:2584–2596.
89. Liang P,Wang Y, Yu X, Dong B. Malignant liver
tumors: treatment with percutaneous microwave
ablation--complications among cohort of 1136
patients. Radiology. 2009;251:933–940.
90. Livraghi T, Meloni F, Solbiati L et al. Compli-
cations of microwave ablation for liver tumors:
Results of a multicenter study. Cardiovasc Inter-
vent Radiol 2012;35:868–874.
91. Lahat E, Eshkenazy R, Zendel A et al. Com-
plications after percutaneous ablation of liver
tumors: A systematic review. Hepatobiliary Surg
Nutr 2014;3:317–323.
This article is available for continuingmedical education credit at CME.TheOncologist.com.CME
© AlphaMed Press 2019www.TheOncologist.com
Izzo, Granata, Grassi et al. e1005
